retatrutide type 2 diabetes trial results 2024 2025 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Triple hormone receptor agonist retatrutide

The study suggests that orthogonal purification technologies like PEC could provide a significant competitive advantage, particularly for organizations looking to enter or expand in this space

These findings underscore the importance of patient risk assessment, follow-up strategies, and tailored interventions to mitigate biliary risks while maintaining therapeutic benefits

In obese individuals, GLP-1 infusion acutely decreased creatinine clearance (29)

With over 20 essential vitamins and minerals (including B12, folate, vitamin D, and iron), a pectin base with prebiotics to support digestion, and a blend of greens and superfoods like kale, spirulina, pomegranate, and acai, it aligns closely with the very gaps smaller appetites can create

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

In a Gut (BMJ) dietary intervention study, individuals with higher Akkermansia muciniphila abundance showed improvements in metabolic markers during the intervention compared with those with lower abundance